Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26254694 | 1.00 | HRH3 (0.39) | HRH3MEN1KMT2A | |
| SCHEMBL15223081 | 1.00 | HRH3 (0.39) | HRH3MEN1KMT2A | |
| SCHEMBL26254285 | 1.00 | HRH3 (0.39) | HRH3MEN1KMT2A | |
| SCHEMBL1753965 | 1.00 | HRH3 (0.39) | HRH3MEN1KMT2A | |
| SCHEMBL26016464 | 1.00 | HRH3 (0.39) | HRH3MEN1KMT2A | |
| SCHEMBL19164021 | 1.00 | HRH3 (0.39) | HRH3MEN1KMT2A | |
| SCHEMBL133695 | 0.96 | HRH3 (0.41) | HRH3 | |
| SCHEMBL24591846 | 0.88 | ALDH1A1 (0.39) | HRH3 | |
| SCHEMBL12042650 | 0.88 | HRH3 (0.35) | HRH3 | |
| SCHEMBL22383865 | 0.88 | HRH3 (0.35) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207415-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20240018101-A1 | MULTIVALENT TERPENE-BASED BOLAAMPHIPHILES FOR GENE DELIVERY | UNIVERSITY OF SAN DIEGO | 2024-01-18 | — | — | US | disclosed |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | ARDELYX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | ARDELYX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11787778-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | MONTELINO THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-8211401-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8158590-B2 | Triazole-containing releasable linkers, conjugates thereof, and methods of preparation | SYNTARGA B.V. (NL) | 2012-04-17 | — | — | US | disclosed |
| US-7955816-B2 | Design and synthesis of biotinylated probes for N-acyl-ethanolamines | Universita Degli Studi Di Roma “Tor Vergata” (IT) | 2011-06-07 | — | — | US | disclosed |
| US-20100330155-A1 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA | FLAGSHIP VENTURES (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100178246-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090118342-A1 | DESIGN AND SYNTHESIS OF BIOTINYLATED PROBES FOR N-ACYL-ETHANOLAMINES | UNIVERSITA' DEGLI STUDI DI ROMA "TOR VERGATA" (IT) | 2009-05-07 | — | — | US | disclosed |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | BYONDIS B.V. (NL) | 2008-12-18 | — | — | US | disclosed |
| US-20080311040-A1 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA | FLAGSHIP VENTURES (US) | 2008-12-18 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178246-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | PSMA1, PSMA5, PSMA3 | HRH3 1695/4885MEN1 12/4885KMT2A 2654/4885 |
| US-11787778-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | AR, ADRM1, PSMA3 | HRH3 3229/4885MEN1 4512/4885KMT2A 1282/4885 |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | REN, NHERF1, KCNJ11 | HRH3 206/4885MEN1 753/4885KMT2A 1804/4885 |
| US-20080311040-A1 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA | NSUN3, AGO2, NSUN2 | HRH3 3777/4885MEN1 4029/4885KMT2A 1414/4885 |
| US-20090118342-A1 | DESIGN AND SYNTHESIS OF BIOTINYLATED PROBES FOR N-ACYL-ETHANOLAMINES | SLC27A2, SLC18A2, FAAH2 | HRH3 335/4885MEN1 1457/4885KMT2A 1107/4885 |
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | PBRM1, SMARCC1, SMARCC2 | HRH3 1124/4885MEN1 1906/4885KMT2A 193/4885 |
| US-20240018101-A1 | MULTIVALENT TERPENE-BASED BOLAAMPHIPHILES FOR GENE DELIVERY | BOLA2; BOLA2B, GHITM, GGPS1 | HRH3 446/4885MEN1 2536/4885KMT2A 2967/4885 |
| US-20240207415-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | HRH3 3229/4885MEN1 4512/4885KMT2A 1282/4885 |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | PAICS, CD44, TRIM33 | HRH3 533/4885MEN1 581/4885KMT2A 2312/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | HRH3 4130/4885MEN1 1550/4885KMT2A 2363/4885 |
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | HRH3 81/4885MEN1 3774/4885KMT2A 1220/4885 |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | HSD11B2, HSD11B1, NR3C2 | HRH3 243/4885MEN1 2049/4885KMT2A 1770/4885 |
| US-20100330155-A1 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA | NSUN3, AGO2, NSUN2 | HRH3 3777/4885MEN1 4029/4885KMT2A 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.